QAL Laws and Regulations Exam Questions with Verified
Correct Answers | Verified Answers with Detailed Rationales
(2026/2027 Edition)
Quality Assurance and Regulatory Compliance Examination
Pharmaceutical, Biotechnology, and Medical Device Industries
SECTION 1: FDA Regulations and Compliance
Question 1
A pharmaceutical company is preparing to submit a New Drug Application (NDA) for a
small molecule drug product. Under the FDA organizational structure, which center
within the Agency holds primary jurisdiction for the review and approval of this
application?
A. Center for Biologics Evaluation and Research (CBER)
B. Center for Drug Evaluation and Research (CDER)
C. Center for Devices and Radiological Health (CDRH)
D. Center for Food Safety and Applied Nutrition (CFSAN)
Correct Answer: B
Rationale: CDER is responsible for regulating drugs, including small molecule
prescription drugs, over-the-counter products, and generic drugs. Option A (CBER)
regulates biological products, blood, vaccines, and cellular and gene therapies. Option C
(CDRH) regulates medical devices and radiological health products. Option D (CFSAN)
regulates food, cosmetics, and dietary supplements. The FD&C Act and FDA's
organizational structure assign drug review authority to CDER.
Question 2
During a routine surveillance inspection of a finished pharmaceutical manufacturing
facility, FDA investigators observe significant deviations from current Good
,Manufacturing Practice. Which of the following represents the MOST serious
administrative enforcement action FDA can take before resorting to judicial
proceedings?
A. Form FDA 483 (Inspectional Observations)
B. Untitled Letter
C. Warning Letter
D. Consent Decree
Correct Answer: C
Rationale: A Warning Letter is FDA's most serious administrative enforcement action,
formally notifying the firm of violations and demanding corrective action within a
specified timeframe (typically 15 working days). Option A (Form 483) is not an
enforcement action but a list of observations made during inspection. Option B (Untitled
Letter) is less serious than a Warning Letter and addresses violations that do not meet
the threshold for a Warning Letter. Option D (Consent Decree) is a court-enforced
settlement agreement and therefore represents judicial, not administrative, action.
Question 3
Under 21 CFR Part 11 (Electronic Records; Electronic Signatures), which requirement
applies to electronic signatures used in electronic records systems governed by
predicate rules?
A. Electronic signatures may be shared among authorized personnel within the same
department to improve workflow efficiency
B. Electronic signatures must be linked to their respective electronic records to ensure
they cannot be removed, copied, or transferred by ordinary means
C. Electronic signatures are only required for batch release records and laboratory test
results
D. Electronic signatures must be accompanied by a handwritten signature on paper
backup for legal enforceability
Correct Answer: B
Rationale: 21 CFR §11.70 requires that electronic signatures be linked to their
respective electronic records so that the signature cannot be excised, copied, or
,otherwise transferred to falsify an electronic record. Option A is incorrect because
electronic signatures must be unique to one individual and not shared. Option C is
incorrect because Part 11 applies to all electronic records required by predicate rules
(e.g., Parts 210, 211, 312), not just batch release and laboratory data. Option D is
incorrect because Part 11 specifically establishes the legal equivalence of electronic
signatures to handwritten signatures, eliminating the need for paper backups.
Question 4
A sponsor submits an Investigational New Drug (IND) application to FDA to begin a
Phase I clinical trial. After preliminary review, FDA determines that the investigational
product presents an unreasonable risk to human subjects. Under 21 CFR Part 312,
which regulatory action will FDA initiate?
A. Issue a Complete Response Letter
B. Place the IND on Clinical Hold
C. Require implementation of a Risk Evaluation and Mitigation Strategy (REMS)
D. Convert the IND to a Treatment IND
Correct Answer: B
Rationale: Under 21 CFR §312.42, FDA may place an IND on clinical hold if the drug
presents unreasonable risk to subjects, if the investigators are not qualified, or if the
investigator brochure is misleading. Option A (Complete Response Letter) is issued in
response to marketing applications (NDA/BLA), not INDs. Option C (REMS) is a
post-marketing risk management tool, not an IND-phase action. Option D (Treatment
IND) refers to expanded access protocols for patients with serious diseases, not a
regulatory hold action.
Question 5
Which regulatory submission pathway requires a medical device manufacturer to
demonstrate that a new device is substantially equivalent to a legally marketed
predicate device?
A. Premarket Approval (PMA)
B. De Novo Classification Request
C. 510(k) Premarket Notification
, D. Investigational Device Exemption (IDE)
Correct Answer: C
Rationale: The 510(k) pathway (21 CFR Part 807, Subpart E) requires demonstration of
substantial equivalence to a predicate device in terms of intended use and
technological characteristics. Option A (PMA) requires independent demonstration of
reasonable assurance of safety and effectiveness for Class III devices. Option B (De
Novo) is used for novel devices of low to moderate risk for which no predicate exists.
Option D (IDE) allows investigational use of a device in clinical trials but does not lead to
marketing clearance.
Question 6
Under the Prescription Drug User Fee Act (PDUFA), FDA has established performance
goals for the review of marketing applications. For a standard New Drug Application
(NDA) that does not receive priority review, the target review timeframe from the date of
submission is:
A. 6 months
B. 10 months
C. 12 months
D. 18 months
Correct Answer: B
Rationale: PDUFA sets a 10-month goal for the review of standard NDAs and BLAs.
Option A (6 months) is the performance goal for priority review applications. Options C
and D exceed current PDUFA performance goals. These timeframes are established in
the PDUFA reauthorization commitments and reflected in FDA guidance.
Question 7
A drug candidate receives Breakthrough Therapy designation from FDA. Which of the
following is the PRIMARY regulatory benefit of this designation?
A. Exemption from Phase III randomized controlled trials
Correct Answers | Verified Answers with Detailed Rationales
(2026/2027 Edition)
Quality Assurance and Regulatory Compliance Examination
Pharmaceutical, Biotechnology, and Medical Device Industries
SECTION 1: FDA Regulations and Compliance
Question 1
A pharmaceutical company is preparing to submit a New Drug Application (NDA) for a
small molecule drug product. Under the FDA organizational structure, which center
within the Agency holds primary jurisdiction for the review and approval of this
application?
A. Center for Biologics Evaluation and Research (CBER)
B. Center for Drug Evaluation and Research (CDER)
C. Center for Devices and Radiological Health (CDRH)
D. Center for Food Safety and Applied Nutrition (CFSAN)
Correct Answer: B
Rationale: CDER is responsible for regulating drugs, including small molecule
prescription drugs, over-the-counter products, and generic drugs. Option A (CBER)
regulates biological products, blood, vaccines, and cellular and gene therapies. Option C
(CDRH) regulates medical devices and radiological health products. Option D (CFSAN)
regulates food, cosmetics, and dietary supplements. The FD&C Act and FDA's
organizational structure assign drug review authority to CDER.
Question 2
During a routine surveillance inspection of a finished pharmaceutical manufacturing
facility, FDA investigators observe significant deviations from current Good
,Manufacturing Practice. Which of the following represents the MOST serious
administrative enforcement action FDA can take before resorting to judicial
proceedings?
A. Form FDA 483 (Inspectional Observations)
B. Untitled Letter
C. Warning Letter
D. Consent Decree
Correct Answer: C
Rationale: A Warning Letter is FDA's most serious administrative enforcement action,
formally notifying the firm of violations and demanding corrective action within a
specified timeframe (typically 15 working days). Option A (Form 483) is not an
enforcement action but a list of observations made during inspection. Option B (Untitled
Letter) is less serious than a Warning Letter and addresses violations that do not meet
the threshold for a Warning Letter. Option D (Consent Decree) is a court-enforced
settlement agreement and therefore represents judicial, not administrative, action.
Question 3
Under 21 CFR Part 11 (Electronic Records; Electronic Signatures), which requirement
applies to electronic signatures used in electronic records systems governed by
predicate rules?
A. Electronic signatures may be shared among authorized personnel within the same
department to improve workflow efficiency
B. Electronic signatures must be linked to their respective electronic records to ensure
they cannot be removed, copied, or transferred by ordinary means
C. Electronic signatures are only required for batch release records and laboratory test
results
D. Electronic signatures must be accompanied by a handwritten signature on paper
backup for legal enforceability
Correct Answer: B
Rationale: 21 CFR §11.70 requires that electronic signatures be linked to their
respective electronic records so that the signature cannot be excised, copied, or
,otherwise transferred to falsify an electronic record. Option A is incorrect because
electronic signatures must be unique to one individual and not shared. Option C is
incorrect because Part 11 applies to all electronic records required by predicate rules
(e.g., Parts 210, 211, 312), not just batch release and laboratory data. Option D is
incorrect because Part 11 specifically establishes the legal equivalence of electronic
signatures to handwritten signatures, eliminating the need for paper backups.
Question 4
A sponsor submits an Investigational New Drug (IND) application to FDA to begin a
Phase I clinical trial. After preliminary review, FDA determines that the investigational
product presents an unreasonable risk to human subjects. Under 21 CFR Part 312,
which regulatory action will FDA initiate?
A. Issue a Complete Response Letter
B. Place the IND on Clinical Hold
C. Require implementation of a Risk Evaluation and Mitigation Strategy (REMS)
D. Convert the IND to a Treatment IND
Correct Answer: B
Rationale: Under 21 CFR §312.42, FDA may place an IND on clinical hold if the drug
presents unreasonable risk to subjects, if the investigators are not qualified, or if the
investigator brochure is misleading. Option A (Complete Response Letter) is issued in
response to marketing applications (NDA/BLA), not INDs. Option C (REMS) is a
post-marketing risk management tool, not an IND-phase action. Option D (Treatment
IND) refers to expanded access protocols for patients with serious diseases, not a
regulatory hold action.
Question 5
Which regulatory submission pathway requires a medical device manufacturer to
demonstrate that a new device is substantially equivalent to a legally marketed
predicate device?
A. Premarket Approval (PMA)
B. De Novo Classification Request
C. 510(k) Premarket Notification
, D. Investigational Device Exemption (IDE)
Correct Answer: C
Rationale: The 510(k) pathway (21 CFR Part 807, Subpart E) requires demonstration of
substantial equivalence to a predicate device in terms of intended use and
technological characteristics. Option A (PMA) requires independent demonstration of
reasonable assurance of safety and effectiveness for Class III devices. Option B (De
Novo) is used for novel devices of low to moderate risk for which no predicate exists.
Option D (IDE) allows investigational use of a device in clinical trials but does not lead to
marketing clearance.
Question 6
Under the Prescription Drug User Fee Act (PDUFA), FDA has established performance
goals for the review of marketing applications. For a standard New Drug Application
(NDA) that does not receive priority review, the target review timeframe from the date of
submission is:
A. 6 months
B. 10 months
C. 12 months
D. 18 months
Correct Answer: B
Rationale: PDUFA sets a 10-month goal for the review of standard NDAs and BLAs.
Option A (6 months) is the performance goal for priority review applications. Options C
and D exceed current PDUFA performance goals. These timeframes are established in
the PDUFA reauthorization commitments and reflected in FDA guidance.
Question 7
A drug candidate receives Breakthrough Therapy designation from FDA. Which of the
following is the PRIMARY regulatory benefit of this designation?
A. Exemption from Phase III randomized controlled trials
